Bisphosphonates as antimyeloma drugs

Leukemia

Volumn 26, Issue 4, 2012, Pages 589-594

  Modi, N D ^a   Lentzsch, S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

bisphosphonates; multiple myeloma; pamidronate; survival; zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CLODRONIC ACID; COMPACTIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FARNESOL; FLUINDOSTATIN; IMMUNOMODULATING AGENT; INTERLEUKIN 6; LONAFARNIB; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; RAS PROTEIN; RISEDRONIC ACID; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE LESION; BONE METASTASIS; BREAST CANCER; BURKITT LYMPHOMA; CANCER CELL; CANCER CELL CULTURE; CELL ADHESION; CELL CYCLE ARREST; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CLINICAL TRIAL (TOPIC); EVENT FREE SURVIVAL; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOLYSIS; PERITONEAL CAVITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PRENYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; TUMOR GROWTH; WESTERN BLOTTING;

BONE MARROW; DIPHOSPHONATES; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA;

EID: 84859639273     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.282     Document Type: Review

References (51)

1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009; 374: 324-339.
2. Corso A, Ferretti E, Lazzarino M. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment. Hematology 2005; 10: 215-224. (Pubitemid 41801138)
3. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996; 87: 1104-1112. (Pubitemid 26043538)
4. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104: 607-618. (Pubitemid 38970551)
5. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175-187. (Pubitemid 37328787)
6. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4: 30-34. (Pubitemid 34097554)
7. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci 2007; 1117: 209-257. (Pubitemid 350191297)
8. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998; 13: 1668-1678. (Pubitemid 28491995)
9. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581-589. (Pubitemid 28163009)
10. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83: 1032-1045.
11. Clezardin P. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone 2011; 48: 71-79.
12. Guenther A, Gordon S, Tiemann M, Burger R, Bakker F, Green JR et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010; 126: 239-246.
13. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96: 384-392. (Pubitemid 30463353)
14. Moschetta M, Di Pietro G, Ria R, Gnoni A, Mangialardi G, Guarini A et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer 2010; 46: 420-429.
15. Ribatti D, Nico B, Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006; 25: 4257-4266. (Pubitemid 44100496)
16. Ribatti D, Vacca A. The role of monocytes-macrophages in vasculogenesis in multiple myeloma. Leukemia 2009; 23: 1535-1536.
17. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007; 13 (15 Pt 1): 4482-4486. (Pubitemid 47219717)
18. Scavelli C, Nico B, Cirulli T, Ria R, Di Pietro G, Mangieri D et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene 2008; 27: 663-674. (Pubitemid 351158901)
19. Baulch-Brown C, Molloy TJ, Yeh SL, Ma D, Spencer A. Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. Leuk Res 2007; 31: 341-352. (Pubitemid 46091701)
20. Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998; 58: 5294-5297. (Pubitemid 28551102)
21. Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997; 98: 665-672. (Pubitemid 27386550)
22. Drexler HG, MacLeod RA, Dirks WG. Cross-contamination: HS-Sultan is not a myeloma but a Burkitt lymphoma cell line. Blood 2001; 98: 3495-3496.
23. Roelofs AJ, Hulley PA, Meijer A, Ebetino FH, Russell RG, Shipman CM. Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells. Int J Cancer 2006; 119: 1254-1261. (Pubitemid 44258797)
24. Lawson MA, Coulton L, Ebetino FH, Vanderkerken K, Croucher PI. Geranylgeranyl transferase type II inhibition prevents myeloma bone disease. Biochem Biophys Res Commun 2008; 377: 453-457.
25. Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003; 18: 482-492. (Pubitemid 36241065)
26. Monkkonen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Vepsalainen J et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 2006; 147: 437-445. (Pubitemid 43292286)
27. Raikkonen J, Monkkonen H, Auriola S, Monkkonen J. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells. Biochem Pharmacol 2010; 79: 777-783.
28. Schmidmaier R, Simsek M, Baumann P, Emmerich B, Meinhardt G. Synergistic antimyeloma effects of zoledronate and simvastatin. Anticancer Drugs 2006; 17: 621-629. (Pubitemid 44265862)
29. Tassone P, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli V et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000; 14: 841-844. (Pubitemid 30235061)
30. Ural AU, Yilmaz MI, Avcu F, Pekel A, Zerman M, Nevruz O et al. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol 2003; 78: 443-449. (Pubitemid 37549625)
31. Casetti R, Martino A. The plasticity of gamma delta T cells: innate immunity, antigen presentation and new immunotherapy. Cell Mol Immunol 2008; 5: 161-170.
32. Fiore F, Castella B, Nuschak B, Bertieri R, Mariani S, Bruno B et al. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity upon short-term incubation with zoledronic acid. Blood 2007; 110: 921-927. (Pubitemid 47267430)
33. Sato K, Kimura S, Segawa H, Yokota A, Matsumoto S, Kuroda J et al. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 2005; 116: 94-99. (Pubitemid 40827760)
34. Yuasa T, Sato K, Ashihara E, Takeuchi M, Maita S, Tsuchiya N et al. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol Immunother 2009; 58: 493-502.
35. Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T et al. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 2009; 37: 956-968.
36. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C et al. Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2010; 14: 2803-2815.
37. Corso A, Ferretti E, Lunghi M, Zappasodi P, Mangiacavalli S, De Amici M et al. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer 2005; 104: 118-125. (Pubitemid 40847759)
38. Berenson JR, Dimopoulos MA, Chen Y-M. Zoledronic acid may improve survival compared to pamidronate in patients with MM and high BALP levels: univariate and multivariate models of hazard ratios. Blood 2006; 108 Abstract 3589.
39. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16: 593-602. (Pubitemid 28135605)
40. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001; 113: 1035-1043. (Pubitemid 32634773)
41. Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007; 24: 227-230. (Pubitemid 350135975)
42. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376: 1989-1999.
43. Kellinsalmi M, Monkkonen H, Monkkonen J, Leskela HV, Parikka V, Hamalainen M et al. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin Pharmacol Toxicol 2005; 97: 382-391. (Pubitemid 43028786)
44. Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 2006; 103: 7829-7834.
45. Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev (Online) 2010, CD003188.
46. McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 1998; 100: 317-325. (Pubitemid 28131063)
47. Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008; 113: 1588-1595.
48. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007; 110: 334-338. (Pubitemid 47026851)
49. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009; 114: 1729-1735.
50. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996; 334: 488-493. (Pubitemid 26067736)
51. Puhaindran ME, Farooki A, Steensma MR, Hameed M, Healey JH, Boland PJ. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J Bone Joint Surg Am 2011; 93: 1235-1242.